Danish Trade Distributors Stock News

Genmab (CPSE:GMAB) opened 2026 with Q1 revenue of US$896 million and basic EPS of US$0.84, setting the tone for how the market will judge its current earnings run versus earlier quarters. Over the past year, reported quarterly revenue has ranged from US$715 million to just over US$1.0 billion, while basic EPS has moved between US$0.50 and US$9.10. This gives you a wide band of outcomes to weigh against the trailing 12 month EPS of US$13.24 and net income of US$821 million. With net margins in...

Solar (CPSE:SOLAR B) has opened 2026 with Q1 revenue of DKK 3.3b and a basic EPS loss of DKK 5.28, while the trailing twelve months show EPS of DKK 7.81 on revenue of DKK 12.3b and net income of DKK 59m. This sets a mixed backdrop for the latest release. Over recent quarters, the company has seen revenue move from DKK 3.2b in Q1 2025 to DKK 3.3b in Q1 2026, with quarterly EPS swinging between a profit of DKK 12.99 in Q4 2025 and a loss of DKK 5.28 in the latest period. With net profit margins...

The quarterly results for Netcompany Group A/S ( CPH:NETC ) were released last week, making it a good time to revisit...

Shareholders of Pandora A/S ( CPH:PNDORA ) will be pleased this week, given that the stock price is up 12% to kr.541...

Vestas Wind Systems A/S ( CPH:VWS ) just released its quarterly report and things are looking bullish. The company beat...

FLSmidth (CPSE:FLS) has secured significant repeat contracts for a major Banded Hematite Quartzite beneficiation project. The orders cover industry leading technologies, including what is described as the world's largest High Pressure Grinding Roll and several large scale stirred media mills. The equipment package is aligned with FLSmidth's MissionZero ambition, aiming to support more sustainable mining operations. The latest awards add substantial contracted work for the coming years for...

How Zealand Pharma Stock Has Been Performing Zealand Pharma (CPSE:ZEAL) has drawn renewed investor attention after a mixed stretch, with the stock showing gains over the past month but negative moves over the past 3 months, year to date, and the past year. Over the past month, the share price return stands at about 5.8%, while the past 3 months show a decline of around 21.1%. Year to date, the stock is down roughly 31.5%, and the past year reflects a total return decline of about...

Q1 2026 results set the tone for NTG Nordic Transport Group (CPSE:NTG) NTG Nordic Transport Group (CPSE:NTG) opened 2026 with Q1 revenue of DKK 2,983 million and basic EPS of DKK 2.62, framing the latest quarterly read alongside a trailing twelve month EPS of DKK 10.14 on revenue of DKK 11.67 billion. Over the past year, the company has seen revenue move from DKK 9.35 billion in the trailing twelve months to Q4 2024 to DKK 11.67 billion by Q1 2026, while trailing EPS shifted from DKK 13.94 to...

Royal Unibrew (CPSE:RBREW) is back in focus after disclosing that its PepsiCo license agreements for Denmark, Finland, and the Baltic states, currently about 13% of net revenue, will expire at the end of 2028. See our latest analysis for Royal Unibrew. Despite the PepsiCo update and a series of recent announcements, including a larger share buyback, AGM approvals and Q1 2026 results, the stock has had a 30 day share price return of a 19.7% decline and a 1 year total shareholder return of a...

Zealand Pharma and Roche have advanced obesity candidate petrelintide into Phase 3 development. Boehringer Ingelheim reported positive Phase III results for obesity drug survodutide, co-invented with Zealand Pharma. Zealand Pharma is eligible for milestone payments and royalties from survodutide, subject to future sales. CPSE:ZEAL is trading at DKK309.0, with the stock down 32.8% year to date and 36.4% over the past 12 months, alongside gains of 39.1% over three years and 57.4% over five...

Recent share moves and business scale Alm. Brand (CPSE:ALMB) has seen mixed returns recently, with the share up 2.9% over the past day but showing declines over the past week, month, and past 3 months. Over longer periods, the stock has delivered a 3.5% 1 year total return and a 44.2% 3 year total return, giving investors context for the recent pullback. The company reported revenue of DKK 13.8b and net income of DKK 1.2b, with both revenue and net income showing annual growth, which helps...

Why Demant Is Back on Value Investors’ Radar Demant (CPSE:DEMANT) has drawn fresh attention after a recent analysis placed it among the most undervalued European stocks, pointing to a sizeable discount to estimated fair value based on discounted cash flows. See our latest analysis for Demant. At a share price of DKK209.0, Demant has seen a 6.85% 1 month share price return. However, the 1 year total shareholder return of 15.79% and 5 year total shareholder return of 35.49% indicate longer term...

The quarterly results for Danske Bank A/S ( CPH:DANSKE ) were released last week, making it a good time to revisit its...

DSV A/S ( CPH:DSV ) shareholders are probably feeling a little disappointed, since its shares fell 6.4% to kr.1,571 in...

Recent geopolitical tensions that earlier led to the closure of the Strait of Hormuz and instability in the Red Sea have forced container carriers such as A.P. Møller - Mærsk to reroute traffic, turning Africa and ports like Saudi Arabia’s Jeddah into new hubs amid longer transit times and congestion. This reshaping of trade lanes underlines how regional ports such as Sohar, Khorfakkan, Fujairah and Jeddah can quickly gain influence when core shipping corridors are disrupted. We’ll now...

As of late April 2026, European markets have been navigating a challenging landscape marked by geopolitical tensions and fluctuating economic indicators. Despite these hurdles, opportunities abound for investors willing to explore beyond the mainstream indices. Penny stocks, though often considered niche investments, can offer intriguing growth potential when they are backed by sound financial fundamentals. In this article, we will examine three European penny stocks that stand out for their...

DSV (CPSE:DSV) opened 2026 with Q1 results anchored by prior quarter revenue of about DKK71.7b and basic EPS of DKK4.72, set against trailing 12 month revenue of roughly DKK247.3b and EPS of DKK35.57. Over recent quarters, revenue has moved from about DKK43.5b in Q4 2024 to the DKK71.7b level in Q4 2025, while quarterly EPS shifted from DKK9.46 to DKK4.72, leaving investors focused on how much of the top line is converting into sustainable margins. See our full analysis for DSV. With the...

Wondering if Rockwool at a last close of DKK 185.8 is starting to look attractive, or if the price still does not quite line up with the underlying business. The stock has been choppy, with a 4.7% decline over the last 7 days, a 6.3% gain over 30 days, and longer-term returns of a 17.2% decline year to date and a 35.4% decline over 1 year, while the 3-year return sits at 19.9% and the 5-year return at a 24.0% decline. Recent coverage around Rockwool has focused on how the share price path...

Why Carlsberg’s expanded PepsiCo partnership matters for shareholders Carlsberg (CPSE:CARL B) has agreed to expand its long running collaboration with PepsiCo, taking over bottling in Denmark, Finland and the Baltic states from 2029 as existing Coca-Cola arrangements conclude. For you as an investor, this shift means Carlsberg is set to handle production, sales and distribution of PepsiCo drinks across all Nordic markets, plus Latvia, Estonia and Lithuania. That extends an arrangement that...

H. Lundbeck (CPSE:HLUN B) shares are in focus after the company reported new 6 month real world INFUSE study results for migraine drug eptinezumab at the American Academy of Neurology 2026 meeting. See our latest analysis for H. Lundbeck. The eptinezumab data arrives at a time when H. Lundbeck’s short term momentum is positive, with a 14.59% 1 month share price return and a 54.44% 1 year total shareholder return. However, the 90 day share price return of 2.16% decline suggests some earlier...

Coloplast recently revised its FY 2025/26 guidance, trimming expected organic growth to 5–6% and EBIT growth to around 5%, while recording a DKK 3.00 billion goodwill impairment on Kerecis following sales disruption from a Medicare reimbursement change and softer skin substitutes demand. This combination of lower growth expectations and a large impairment charge highlights how reimbursement shifts in a single niche can materially affect Coloplast’s broader outlook and capital allocation...

Royal Unibrew A/S has reported its Q1 2026 results, with sales rising to DKK 3,311 million and net income increasing to DKK 171 million, alongside basic and diluted earnings per share from continuing operations of DKK 3.5, all up from the same period last year. The company’s 25% EBIT increase, driven by margin expansion and market share gains while reaffirming its full-year 2026 outlook and running a share buyback program through August 14, 2026, highlights a focus on profitability and...

Wondering whether A.P. Møller - Mærsk is priced attractively right now, or if the recent run leaves less room for value focused investors. The share price closed at DKK 14,990, with a 1 year return of 43.3% and a 5 year return of 87.0%, while shorter term moves include a 7 day return of 5.9% decline and a 30 day return of 13.0% decline, with a 2.0% gain year to date. Recent share price moves sit against a backdrop of ongoing interest in global shipping and logistics, where investors continue...

We'd be surprised if SKAKO A/S ( CPH:SKAKO ) shareholders haven't noticed that the MD, CEO & Non-Independent Director...